Perrigo appoints chief scientific officer
Ireland-incorporated generic and OTC drugmaker Perrigo (NYSE, TASE: PRGO) today announced that James Dillard has been appointed executive vice president and chief scientific officer.
In this new role, Mr Dillard will be responsible for providing global oversight and coordination of Perrigo's R&D, quality, regulatory and innovation efforts. He will report to president and chief executive Murray Kessler.
Commenting on the appointment, Mr Kessler stated: "Jim and I have previously worked together for many years. He has a proven 31-year track record in regulated consumer and medical products, US Food and Drug Administration (FDA) regulatory affairs and consumer product development. Over the course of his career Jim has led the successful development and introduction of many major new products as well as actively built innovative capabilities, frameworks and research strategies."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze